(ICAD) icad - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US44934S2068

ICAD: Cancer, Detection, Therapy, Solutions, Breast, Imaging, Software

iCAD, Inc. (NASDAQ:ICAD) is a leading provider of innovative cancer detection and therapy solutions, operating through two core segments: Detection and Therapy. The company specializes in advanced imaging and radiation therapy solutions, focusing on improving patient outcomes in oncology. Its product portfolio includes ProFound AI, a cutting-edge solution for digital breast tomosynthesis and 2D mammography; PowerLook, a tool for breast density assessment; and ProFound Risk, which offers personalized breast cancer risk analysis. These solutions leverage AI and machine learning to enhance diagnostic accuracy and patient care.

Founded in 1984 under the name Howtek, Inc., the company rebranded as iCAD, Inc. in 2002 to reflect its expanded focus on medical imaging and cancer detection. Headquartered in Nashua, New Hampshire, iCAD has established itself as a key player in the medical technology sector, particularly in the areas of breast health and radiation oncology. Its commitment to innovation has positioned it at the forefront of AI-driven healthcare solutions.

From a technical standpoint, ICADs stock has shown volatility, with a 20-day average volume of 447,048 shares. The stock is currently trading at $2.25, below its 20-day SMA of $2.94 and 50-day SMA of $2.54. The 200-day SMA stands at $1.81, indicating potential long-term upside. The ATR of $0.30 reflects moderate price fluctuations. On the fundamental side, the company has a market cap of $66.94 million, with a price-to-book ratio of 2.28 and a price-to-sales ratio of 3.53. The negative return on equity (-11.58%) highlights ongoing profitability challenges.

3-Month Forecast: Based on and , ICAD is expected to face near-term headwinds due to its current price trending below key moving averages. The stock may test support levels near $2.00 in the next month, with potential resistance at $3.00. The ATR of $0.30 suggests moderate volatility, with price movements likely driven by news-related catalysts. On the fundamental side, the companys high P/S ratio of 3.53 may indicate rich valuation, potentially limiting upside unless revenue growth accelerates. Overall, the stock is likely to remain range-bound in the short term, with a neutral to slightly bearish outlook.

Additional Sources for ICAD Stock

ICAD Stock Overview

Market Cap in USD 58m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Technology
IPO / Inception 1986-12-03

ICAD Stock Ratings

Growth 5y -50.8%
Fundamental -41.9%
Dividend 0.0%
Rel. Strength Industry 41
Analysts 4.75/5
Fair Price Momentum 1.84 USD
Fair Price DCF -

ICAD Dividends

No Dividends Paid

ICAD Growth Ratios

Growth Correlation 3m 61.6%
Growth Correlation 12m 69.1%
Growth Correlation 5y -82.6%
CAGR 5y -21.95%
CAGR/Max DD 5y -0.23
Sharpe Ratio 12m -0.05
Alpha 19.47
Beta 2.86
Volatility 78.40%
Current Volume 216.6k
Average Volume 20d 385.7k
What is the price of ICAD stocks?
As of March 16, 2025, the stock is trading at USD 2.29 with a total of 216,583 shares traded.
Over the past week, the price has changed by +2.23%, over one month by -31.02%, over three months by +26.52% and over the past year by +42.24%.
Is icad a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, icad (NASDAQ:ICAD) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -41.89 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ICAD as of March 2025 is 1.84. This means that ICAD is currently overvalued and has a potential downside of -19.65%.
Is ICAD a buy, sell or hold?
icad has received a consensus analysts rating of 4.75. Therefor, it is recommend to buy ICAD.
  • Strong Buy: 3
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ICAD stock price target?
According to ValueRays Forecast Model, ICAD icad will be worth about 2.2 in March 2026. The stock is currently trading at 2.29. This means that the stock has a potential downside of -4.37%.
Issuer Forecast Upside
Wallstreet Target Price 4.5 96.5%
Analysts Target Price 4.4 91.3%
ValueRay Target Price 2.2 -4.4%